<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND:: In vitro studies in mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) cell lines and patient-derived cells have demonstrated synergistic <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with combined rituximab and <z:chebi fb="0" ids="52717">bortezomib</z:chebi> (R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi>) compared with single-agent <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, the authors of this report evaluated R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi> in a preclinical model and in a phase 2 clinical trial </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS:: A Hu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-<z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:mp ids='MP_0002536'>SCID</z:mp>) model engrafted with the Jeko cell line was treated with R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi>, <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, or rituximab </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-five patients with relapsed follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 11) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (n = 14) received 375 mg/m(2) rituximab on Days 1 and 8 and 1.3 to 1.5 mg/m(2) <z:chebi fb="0" ids="52717">bortezomib</z:chebi> on Days 1, 4, 8, and 11 every 21 days for a median of 3 cycles (range, 1-5 cycles) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS:: R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi> resulted in a statistically significant improvement in overall survival in Hu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-<z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="5" pm="."><plain>In the clinical trial, the overall response rate was 40% in <z:hpo ids='HP_0000001'>all</z:hpo> 25 patients, 55% in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 29% in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The estimated 2-year progression-free survival (PFS) rate was 24% (95% confidence interval [CI], 10%-53%) in <z:hpo ids='HP_0000001'>all</z:hpo> patients and 60% (95% CI, 20%-85%) in responding patients </plain></SENT>
<SENT sid="7" pm="."><plain>Thirteen patients (52%) developed grade 3 neurotoxicity, which consisted of <z:hpo ids='HP_0002019'>constipation</z:hpo>/<z:hpo ids='HP_0002595'>ileus</z:hpo>, sensory or <z:e sem="disease" ids="C0235025" disease_type="Disease or Syndrome" abbrv="">motor neuropathy</z:e>, or <z:hpo ids='HP_0001278'>orthostatic hypotension</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who were heterozygous for the CD32a (Fcγ receptor IIa) 131 histidine (H) to arginine (R) polymorphism had a significantly decreased PFS (P = .009) after R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi> compared with HH and RR homozygotes </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS:: R-<z:chebi fb="0" ids="52717">bortezomib</z:chebi> had significant activity in patients with relapsed or refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, although an unexpectedly high incidence of grade 3 neurologic toxicity was a potential limiting factor with this combination </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> 2011. © 2010 American <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Society </plain></SENT>
</text></document>